HaroldN.KeerMDPhD

Genitourinary Oncology, Hematologic Oncology

Chief Medical Officer, Taiho Oncology, Inc.

Dr. Keer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Oncologist leading R& D efforts at Taiho Oncology, Inc. as Chief Medical Officer

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1994 - 1997
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1990 - 1993
Northwestern University The Feinberg School of MedicineClass of 1990

PubMed

1 citations
Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study.
Klaus Geissler, Zdenek Koristek, Teresa Bernal Del Castillo, Jan Novák, Gabriela Rodríguez-Macías
British Journal of Haematology. 2024-11-01
Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma.
George A Ward, Zhiqiang Zhang, Simone Jueliger, Ilya S Potapov, Matthew P Davis
Cancer Research Communications. 2024-06-06
Real-world study of the use of azacitidine in myelodysplasia in Australia.
Anoop Enjeti, Asma Ashraf, Vincent Caillet, Arif Alam, Jonathan Silar
Ejhaem. 2024-06-01

Abstracts/Posters

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...
Harold N. Keer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Taiho Oncology Data at ASH Annual Meeting Highlight Progress in Oral Therapies for Patients with Blood CancersDecember 9th, 2024
Astex Announces That the Phase 3 ASCERTAIN - Acute Myeloid Leukemia (AML) Clinical Study of Oral Hypomethylating Agent Decitabine and Cedazuridine Fixed-Dose Combination (ASTX727 or DEC-C) Met the Trial’s Primary EndpointMay 12th, 2022